Total Payments
$144,838
2024 Payments
$22,305
Companies
18
Transactions
425
Medicare Patients
662
Medicare Billing
$117,257
Payment Breakdown by Category
Other$93,741 (64.7%)
Consulting$30,300 (20.9%)
Food & Beverage$13,254 (9.2%)
Travel$7,453 (5.1%)
Education$89.46 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $93,741 | 65 | 64.7% |
| Consulting Fee | $30,300 | 10 | 20.9% |
| Food and Beverage | $13,254 | 282 | 9.2% |
| Travel and Lodging | $7,453 | 64 | 5.1% |
| Education | $89.46 | 4 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $63,832 | 140 | $0 (2024) |
| ABBVIE INC. | $40,773 | 108 | $0 (2024) |
| Axsome Therapeutics, Inc. | $35,135 | 59 | $0 (2024) |
| ITI, Inc. | $995.45 | 26 | $0 (2023) |
| Neurocrine Biosciences, Inc. | $817.80 | 16 | $0 (2024) |
| Allergan, Inc. | $777.51 | 13 | $0 (2020) |
| Teva Pharmaceuticals USA, Inc. | $759.47 | 12 | $0 (2024) |
| Lundbeck LLC | $403.70 | 17 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $314.27 | 4 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $248.95 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $22,305 | 74 | Axsome Therapeutics, Inc. ($16,763) |
| 2023 | $39,624 | 114 | Axsome Therapeutics, Inc. ($18,354) |
| 2022 | $24,484 | 78 | ABBVIE INC. ($15,108) |
| 2021 | $12,167 | 32 | AbbVie Inc. ($9,120) |
| 2020 | $5,742 | 14 | Otsuka America Pharmaceutical, Inc. ($5,539) |
| 2019 | $13,511 | 45 | Otsuka America Pharmaceutical, Inc. ($12,176) |
| 2018 | $14,402 | 37 | Otsuka America Pharmaceutical, Inc. ($13,834) |
| 2017 | $12,603 | 31 | Otsuka America Pharmaceutical, Inc. ($12,356) |
All Payment Transactions
425 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $23.63 | General |
| Category: PSYCHIATRY | ||||||
| 12/03/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: NEUROSCIENCE | ||||||
| 11/26/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $28.53 | General |
| Category: Neuropsychiatry | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $21.47 | General |
| 11/13/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $48.83 | General |
| Category: Psychology/Psychiatric | ||||||
| 11/12/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $23.76 | General |
| Category: PSYCHIATRY | ||||||
| 10/22/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $25.07 | General |
| Category: PSYCHIATRY | ||||||
| 10/15/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: PSYCHIATRY | ||||||
| 10/08/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $28.33 | General |
| Category: Central Nervous System | ||||||
| 09/24/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $19.65 | General |
| Category: PSYCHIATRY | ||||||
| 09/18/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $20.24 | General |
| Category: PSYCHIATRY | ||||||
| 09/10/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $24.28 | General |
| Category: PSYCHIATRY | ||||||
| 09/06/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Psychology/Psychiatric | ||||||
| 09/06/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Travel and Lodging | Cash or cash equivalent | $26.13 | General |
| Category: Psychology/Psychiatric | ||||||
| 09/06/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Travel and Lodging | Cash or cash equivalent | $2.09 | General |
| Category: Psychology/Psychiatric | ||||||
| 09/04/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.34 | General |
| Category: NEUROSCIENCE | ||||||
| 08/20/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Psychology/Psychiatric | ||||||
| 08/20/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Psychology/Psychiatric | ||||||
| 08/20/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Travel and Lodging | Cash or cash equivalent | $26.80 | General |
| Category: Psychology/Psychiatric | ||||||
| 08/20/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Travel and Lodging | Cash or cash equivalent | $21.74 | General |
| Category: Psychology/Psychiatric | ||||||
| 08/20/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: PSYCHIATRY | ||||||
| 08/13/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $24.65 | General |
| Category: Neuropsychiatry | ||||||
| 08/07/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $118.74 | General |
| Category: Central Nervous System | ||||||
| 08/06/2024 | ABBVIE INC. | VRAYLAR (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,125.00 | General |
| Category: NEUROSCIENCE | ||||||
| 08/06/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: PSYCHIATRY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 125 | 241 | $39,814 | $17,500 |
| 2022 | 3 | 153 | 433 | $55,354 | $31,421 |
| 2021 | 3 | 151 | 472 | $53,435 | $33,440 |
| 2020 | 3 | 233 | 534 | $80,930 | $34,896 |
Total Patients
662
Total Services
1,680
Medicare Billing
$117,257
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 88 | 169 | $21,598 | $9,868 | 45.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 37 | 72 | $18,216 | $7,632 | 41.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 95 | 342 | $29,451 | $20,440 | 69.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 43 | 59 | $14,927 | $5,998 | 40.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 15 | 32 | $10,976 | $4,983 | 45.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 100 | 393 | $33,534 | $23,918 | 71.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 40 | 68 | $17,204 | $7,527 | 43.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 11 | 11 | $2,697 | $1,995 | 74.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 158 | 399 | $47,848 | $21,933 | 45.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 64 | 124 | $29,893 | $11,119 | 37.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 11 | 11 | $3,189 | $1,844 | 57.8% |
About Dr. Alla Nirenberg, M.D
Dr. Alla Nirenberg, M.D is a Psychiatry healthcare provider based in Elmsford, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336223544.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alla Nirenberg, M.D has received a total of $144,838 in payments from pharmaceutical and medical device companies, with $22,305 received in 2024. These payments were reported across 425 transactions from 18 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($93,741).
As a Medicare-enrolled provider, Nirenberg has provided services to 662 Medicare beneficiaries, totaling 1,680 services with total Medicare billing of $117,257. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Elmsford, NY
- Active Since 10/24/2006
- Last Updated 07/08/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1336223544
Products in Payments
- REXULTI (Drug) $63,921
- VRAYLAR (Drug) $41,550
- Auvelity (Drug) $35,135
- CAPLYTA (Drug) $1,217
- INGREZZA (Drug) $817.80
- AUSTEDO (Drug) $533.34
- SPRAVATO (Drug) $314.27
- LATUDA (Drug) $248.95
- MYDAYIS (Drug) $240.61
- Austedo XR (Drug) $226.13
- ABILIFY MAINTENA (Drug) $215.35
- LOREEV XR (Drug) $81.37
- GRALISE (Drug) $56.68
- PERSERIS (Drug) $49.04
- JORNAY PM (Drug) $23.03
- Trintellix (Drug) $11.05
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.